Clinical trial NCT00133107: Safety and Effectiveness of Efalizumab to Treat Oral Lichen Planus
Official title: A Single Center, Open-label, Pilot Study Evaluating the Safety and Effectiveness of Subcutaneous Efalizumab in the Treatment of Oral Lichen Planus
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Lichen Planus, Oral
Lead sponsor: Washington University School of Medicine
Sponsor class: OTHER
Collaborators: name: Genentech, Inc.
First posted: 2005-08-22
Enrollment: 4
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is to determine whether efalizumab 1.0mg/kg given by subcutaneous injection for 12 weeks is effective in treating oral lichen planus.

This is a 20 week, single center, open-label pilot study to enroll 5 subjects.


Eligibility criteria: Inclusion Criteria:

* Able to provide written informed consent
* Subject able and willing to comply with study requirements for the full duration of the study.
* Age \> 18 years.
* Subject has a diagnosis of oral lichen planus deemed by the investigator to be of sufficient severity to require systemic agents. The diagnosis can be made by biopsy proven oral lichen planus or biopsy proven cutaneous lichen planus in the setting of a subject with oral disease consistent with lichen planus.
* Subject has a clinical lesion score of at least 2.
* If female of childbearing potential, subject will have a negative urine pregnancy test at screening and week 0.
* If female, subject will be either post-menopausal for \> 1 year; surgically sterile (hysterectomy or bilateral tubal ligation); or practicing one form of birth control (abstinence, oral contraceptive, estrogen patch, implant contraception, injectable contraception, intrauterine device \[IUD\], diaphragm, condom, sponge, spermicides, or vasectomy of partner). Female subjects will continue to use contraception for 3 months following the last injection.
* Subjects must be on stable doses of topical medications, such as corticosteroids, cyclosporine, and tacrolimus for the past 4 weeks.

Exclusion Criteria:

* Patients with known hypersensitivity to Raptiva (efalizumab) or any of its components.
* Pregnant or lactating women
* Subject has evidence of a clinically significant, unstable or poorly controlled medical condition.
* Subject has a chest X-ray consistent with an active infection or previous exposure to tuberculosis (TB) and/or a positive purified protein derivative test at screening (\> 5 mm). (Subjects may participate if they are being actively treated in accordance with Centers for Disease Control \[CDC\] guidelines.)
* Subject has a serious, active or recurrent bacterial, viral, or fungal infection. This includes hepatitis B and C, and HIV.
* Subject has been hospitalized for infection or received intravenous (IV) antibiotics within the previous 2 months prior to baseline.
* Subject has a history of tuberculosis without documented adequate therapy.
* Subject has been diagnosed with a malignancy within the past 5 years except for successfully treated non-melanoma skin cancer.
* Subject has any dermatologic disease in the target site that may be exacerbated by treatment or interfere with examination.
* Subject has been administered an investigational drug in another clinical study within 30 days prior to baseline (or 5 half-lives, whichever is longer). Subjects in observational studies without investigational drugs or devices may still be enrolled.
* Subject has used the following systemic agents within 4 weeks prior to week 0: photochemotherapy, systemic corticosteroids, cyclosporine, tacrolimus, azathioprine, methotrexate, mycophenolate mofetil, hydroxychloroquine, chloroquine, quinacrine, dapsone, or thalidomide.
* Subject has previously been treated with biologic immune response modifiers including alefacept, etanercept, infliximab, or adalimumab within 12 weeks prior to day 0 (or 5 half-lives, whichever is longer).
* Subject has previously been treated with efalizumab.
* Subject weighs over 125 kg.

Primary outcomes:
measure: primary efficacy measure will be oral mucosal surface area involvement
timeFrame: 12 weeks
Secondary outcomes:
measure: clinical lesion score
timeFrame: Week 0, 1, 4, 8, 12, and 20
measure: ten centimeter visual analogue pain scale
timeFrame: Week 0, 1, 4, 8, 12, and 20
measure: oral health impact profile-14 questionnaire
timeFrame: Week 0, 1, 4, 8, 12, and 20
measure: cutaneous surface area involvement
timeFrame: Week 0, 1, 4, 8, 12, and 20
Other outcomes:
Locations:
city: St. Louis
country: United States
facility: Washington University
state: Missouri
Study officials:
affiliation: Washington University School of Medicine
name: Michael P. Heffernan, MD
role: PRINCIPAL_INVESTIGATOR
References: